Oxymorphone (original) (raw)
أوكسي مورفون Oxymorphone
| Property | Value |
|---|---|
| dbo:abstract | أوكسي مورفون Oxymorphone (ar) Oxymorphon ist ein stark schmerzstillend wirkender Arzneistoff (Analgetikum). Die Substanz ist ein halbsynthetisch hergestelltes Opioid und wirkt etwa zehnmal so stark wie Morphin. Oxymorphon wird in der Akut- und Langzeit-Schmerztherapie bei starken bis sehr starken Schmerzen eingesetzt. Oxymorphon wurde von M. J. Lewenstein und U. Weiss entdeckt und am 10. September 1957 unter der Nummer US 2806033 in den Vereinigten Staaten patentiert und 1995 von der Arzneimittelzulassungsbehörde FDA zugelassen. (de) La Oximorfona, que se vende bajo las marcas Numorphan entre otras, es un potente analgésico opioide semisintético. El alivio del dolor después de la inyección comienza después de aproximadamente 5 a 10 minutos y 15 a 30 minutos después de la administración rectal, y dura aproximadamente de 3 a 4 horas para las tabletas de liberación inmediata y 12 horas para las tabletas de liberación prolongada. Fue desarrollado en Alemania en 1914. Fue patentado en 1955 y aprobado para uso médico en 1959. Es altamente adictivo y en junio de 2017, la FDA solicitó al fabricante que retirara su producto del mercado estadounidense. Esto se debió en parte a la epidemia de opioides en los EE. UU. Y al hecho de que la reformulación de 2012 provocó un cambio en la ruta del abuso de nasal a inyección. En respuesta, en julio de 2017, Endo International retiró voluntariamente Opana ER del mercado. Las versiones genéricas de oximorfona de aún están disponibles para su uso con receta en los Estados Unidos. (es) L’oxymorphone (Opana, Numorphan, Numorphone) ou 14-Hydroxydihydromorphinone est un puissant analgésique opioïde semi-synthétique d’abord développé en Allemagne vers 1914, brevetée aux États-Unis par la compagnie pharmaceutique Endo Pharmaceuticals en 1955 et introduite sur le marché américain en janvier 1959 et par la suite dans de nombreux autres pays à travers le monde. Dans certains pays, l’oxymorphone est distribué sous le nom de Numorphan et Numorphan Oral. Il diffère de la morphine au niveau des effets secondaires car il semble produire moins de sédation, de démangeaisons et d’autres effets du à une libération excessive d’histamine, comme tous les opiacés. Selon le patient, il peut créer plus ou moins de nausée et vomissement que la morphine. L’oxymorphone est administrée sous forme de sel de chlorhydrate par injection ou par un suppositoire, généralement à des doses de 1 mg (injection) à 5 mg (suppositoire). Endo a été le principal distributeur d’oxymorphone à travers le monde et est présentement distribué aux États-Unis et ailleurs sous le nom d'Opana et Opana ER. La durée d’action de l’oxymorphone est de 5 à 8 heures selon les patients.L’oxymorphone est également produite dans le corps humain lorsque le foie métabolise de l’oxycodone.La consommation d'alcool associée à des comprimés à libération prolongée peut être extrêmement dangereuse. Son absorption peut être potentialisée fortement en présence d'alcool, ce qui peut créer une surdose. (fr) Oxymorphone (sold under the brand names Numorphan and Opana among others) is a highly potent opioid analgesic indicated for treatment of severe pain. Pain relief after injection begins after about 5–10 minutes, after oral administration it begins after about 30 minutes, and lasts about 3–4 hours for immediate-release tablets and 12 hours for extended-release tablets. The elimination half-life of oxymorphone is much faster intravenously, and as such, the drug is most commonly used orally. Like oxycodone, which metabolizes to oxymorphone, oxymorphone has a high potential to be abused. It was developed in Germany in 1914. It was patented in 1955 and approved for medical use in 1959. In June 2017 the FDA asked Endo Pharmaceuticals to remove its product from the US market. This was in part due to the opioid epidemic in the US, and the fact that a 2012 reformulation failed to stop illicit injection of the drug. Endo responded by voluntarily removing Opana ER from the market a month later. Generic versions of extended-release oxymorphone, such as those manufactured by Amneal Pharmaceuticals, are still available in the US. (en) Ossimorfone è un potente analgesico oppioide semisintetico sviluppato per la prima volta in Germania nel 1914, brevettato negli USA dalla Endo Pharmaceuticals nel 1955 e introdotto per il mercato degli Stati Uniti nel gennaio 1959 e in altri paesi allo stesso tempo. Il composto è stato progettato per avere minore incidenza di effetti collaterali rispetto alla morfina e all'eroina. (it) Oksymorfon – organiczny związek chemiczny, półsyntetyczny opioid. Znajduje się w grupie I-N Ustawy o przeciwdziałaniu narkomanii. Jest objęty Jednolitą konwencją o środkach odurzających z 1961 roku (wykaz I). (pl) Oximorfon, summaformel C17H19NO4, är en kraftigt smärtstillande opioid. Substansen utvinns ur morfinderivatet tebain och är 6-8 gånger så potent som morfin. För närvarande[när?] finns inga läkemedel med oximorfon registrerade i Sverige, och är därför mycket sällsynt förekommande. Det ringa förekomsten av substansen på svarta marknaden i Sverige tros härstamma från smuggling från utlandet. Substansen är narkotikaklassad och ingår i förteckningen N I i 1961 års allmänna narkotikakonvention, samt i förteckning II i Sverige. (sv) Оксиморфо́н или 14-гидроксидигидроморфинон (продается под торговыми марками Numorphan и Opana) — мощный полусинтетический опиоидный анальгетик. Препарат предназначен для уменьшения сильной боли. Облегчение боли после инъекции начинается примерно через 5–10 минут, после перорального приема препарат начинает действовать примерно через 30 минут (и длится около 3–4 часов). Период полувыведения оксиморфона намного быстрее при внутривенном введении, и поэтому препарат чаще всего используется перорально. Как и оксикодон, который метаболизируется в оксиморфон, оксиморфон имеет высокий потенциал злоупотребления. (ru) |
| dbo:alternativeName | Numorphan, Numorphone, Opana, others (en) |
| dbo:casNumber | 76-41-5 |
| dbo:chEMBL | 963 |
| dbo:drugbank | DB01192 |
| dbo:fdaUniiCode | 9VXA968E0C |
| dbo:kegg | D08323 |
| dbo:medlinePlus | a610022 |
| dbo:pubchem | 5284604 |
| dbo:thumbnail | wiki-commons:Special:FilePath/Oxymorphone2DCSD.svg?width=300 |
| dbo:wikiPageExternalLink | https://books.google.com/books%3Fid=o_rHHCsIpckC&pg=PA332%7Cdate=25 |
| dbo:wikiPageID | 881753 (xsd:integer) |
| dbo:wikiPageLength | 33878 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1115787483 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Bradycardia dbr:Apnea dbr:Hydrocodone dbr:Hydromorphone dbr:Dose_(biochemistry) dbr:Intramuscular_injection dbr:Intravenous_therapy dbr:Platinum dbr:Binding_affinity dbr:Route_of_administration dbr:Δ-opioid_receptor dbr:Thrombotic_microangiopathy dbc:4,5-Epoxymorphinans dbc:Cyclohexanols dbc:Ethers dbc:Ketones dbc:Mu-opioid_receptor_agonists dbc:Phenols dbc:Semisynthetic_opioids dbc:Tertiary_alcohols dbr:Controlled_Substances_Act dbr:Opium_poppy dbr:Oral_administration dbr:Codeine dbr:Endo_Pharmaceuticals dbr:Germany dbr:Morphine dbr:Naloxone dbr:Thebaine dbr:Opioid_antagonist dbr:Opioid_epidemic dbr:Anti-Heroin_Act_of_1924 dbr:Liver dbr:Subcutaneous_injection dbr:Austin,_Indiana dbc:German_inventions dbr:Thrombotic_thrombocytopenic_purpura dbr:Acetylmorphone dbr:Amneal_Pharmaceuticals dbr:Analgesic dbc:Euphoriants dbr:Drug_Enforcement_Administration dbr:Ethanol dbr:FDA dbr:Oxycodone dbr:Oxymorphazone dbr:Oxymorphol dbr:Palladium dbr:Cardiac_arrest dbr:Glucuronidation dbr:Heroin dbr:Hydrochloride dbr:Hypotension dbr:Μ-opioid_receptor dbr:ADAMTS13 dbr:Modified-release_dosage dbr:Dihydrocodeine dbr:Dihydromorphine dbr:CYP2D6 dbr:CYP3A4 dbr:Circulatory_collapse dbr:Opioid dbr:Pharmacokinetics dbr:Κ-opioid_receptor dbr:Oriental_poppy dbr:Plasma_exchange dbr:Flaccidity dbr:Dionine dbr:ACSCN |
| dbp:atcPrefix | N02 (en) |
| dbp:atcSuffix | AA11 (en) |
| dbp:bioavailability | Buccal: 28% (en) IV, IM & IT: 100% (en) Intranasal: 43% (en) Sublingual: 37.5% (en) by mouth: 10% (en) |
| dbp:c | 17 (xsd:integer) |
| dbp:casNumber | 76 (xsd:integer) |
| dbp:chembl | 963 (xsd:integer) |
| dbp:chemspiderid | 4447650 (xsd:integer) |
| dbp:dailymedid | Oxymorphone (en) |
| dbp:drugbank | DB01192 (en) |
| dbp:eliminationHalfLife | -21600.0 (dbd:second) |
| dbp:excretion | Urine, feces (en) |
| dbp:h | 19 (xsd:integer) |
| dbp:image | Oxymorphone3DanJ.gif (en) |
| dbp:iupacName | 45 (xsd:integer) |
| dbp:iupharLigand | 7094 (xsd:integer) |
| dbp:kegg | D08323 (en) |
| dbp:legalAu | S8 (en) |
| dbp:legalCa | Schedule I (en) |
| dbp:legalDe | Anlage II (en) |
| dbp:legalUk | Class A (en) |
| dbp:legalUs | dbr:Controlled_Substances_Act |
| dbp:medlineplus | a610022 (en) |
| dbp:metabolism | Liver (en) |
| dbp:n | 1 (xsd:integer) |
| dbp:o | 4 (xsd:integer) |
| dbp:proteinBound | 10.0 (dbd:perCent) |
| dbp:pubchem | 5284604 (xsd:integer) |
| dbp:routesOfAdministration | By mouth, buccal, sublingual, intranasal, intravenous, epidural, subcutaneous, intramuscular (en) |
| dbp:smiles | CN1CC[C@]23c4c5cccc4O[C@H]2CCC[C@@]3[C@H]1C5 (en) |
| dbp:stdinchi | 1 (xsd:integer) |
| dbp:stdinchikey | UQCNKQCJZOAFTQ-ISWURRPUSA-N (en) |
| dbp:synonyms | 14 (xsd:integer) |
| dbp:tradename | Numorphan, Numorphone, Opana, others (en) |
| dbp:unii | 9 (xsd:integer) |
| dbp:verifiedrevid | 456483627 (xsd:integer) |
| dbp:watchedfields | changed (en) |
| dbp:width | 170 (xsd:integer) 250 (xsd:integer) |
| dbp:wikiPageUsesTemplate | dbt:Abbr dbt:Analgesics dbt:Citation_needed dbt:Commons_category-inline dbt:Distinguish dbt:Drugbox dbt:Reflist dbt:See_also dbt:Short_description dbt:When dbt:Abbrlink dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Ebicite dbt:Fdacite dbt:Keggcite dbt:Stdinchicite dbt:Opioid_receptor_modulators dbt:Drugs.com |
| dct:subject | dbc:4,5-Epoxymorphinans dbc:Cyclohexanols dbc:Ethers dbc:Ketones dbc:Mu-opioid_receptor_agonists dbc:Phenols dbc:Semisynthetic_opioids dbc:Tertiary_alcohols dbc:German_inventions dbc:Euphoriants |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:Ability105616246 yago:Abstraction100002137 yago:Agent114778436 yago:Alcohol107884567 yago:Beverage107881800 yago:CausalAgent100007347 yago:Chemical114806838 yago:Cognition100023271 yago:Compound114818238 yago:Creativity105624700 yago:Drug103247620 yago:DrugOfAbuse103248958 yago:Element114840755 yago:Fluid114939900 yago:Food100021265 yago:Invention105633385 yago:Ketone114926294 yago:Liquid114940386 yago:Material114580897 yago:Matter100020827 yago:OrganicCompound114727670 yago:Part113809207 yago:Phenol114989545 yago:PhysicalEntity100001930 yago:PsychologicalFeature100023100 yago:Quintessence114847103 yago:Relation100031921 yago:WikicatGermanInventions yago:WikicatKetones dbo:Drug yago:Substance100019613 yago:Substance100020090 yago:WikicatAlcohols yago:WikicatEthers yago:WikicatPhenols umbel-rc:DrugProduct |
| rdfs:comment | أوكسي مورفون Oxymorphone (ar) Oxymorphon ist ein stark schmerzstillend wirkender Arzneistoff (Analgetikum). Die Substanz ist ein halbsynthetisch hergestelltes Opioid und wirkt etwa zehnmal so stark wie Morphin. Oxymorphon wird in der Akut- und Langzeit-Schmerztherapie bei starken bis sehr starken Schmerzen eingesetzt. Oxymorphon wurde von M. J. Lewenstein und U. Weiss entdeckt und am 10. September 1957 unter der Nummer US 2806033 in den Vereinigten Staaten patentiert und 1995 von der Arzneimittelzulassungsbehörde FDA zugelassen. (de) Ossimorfone è un potente analgesico oppioide semisintetico sviluppato per la prima volta in Germania nel 1914, brevettato negli USA dalla Endo Pharmaceuticals nel 1955 e introdotto per il mercato degli Stati Uniti nel gennaio 1959 e in altri paesi allo stesso tempo. Il composto è stato progettato per avere minore incidenza di effetti collaterali rispetto alla morfina e all'eroina. (it) Oksymorfon – organiczny związek chemiczny, półsyntetyczny opioid. Znajduje się w grupie I-N Ustawy o przeciwdziałaniu narkomanii. Jest objęty Jednolitą konwencją o środkach odurzających z 1961 roku (wykaz I). (pl) Oximorfon, summaformel C17H19NO4, är en kraftigt smärtstillande opioid. Substansen utvinns ur morfinderivatet tebain och är 6-8 gånger så potent som morfin. För närvarande[när?] finns inga läkemedel med oximorfon registrerade i Sverige, och är därför mycket sällsynt förekommande. Det ringa förekomsten av substansen på svarta marknaden i Sverige tros härstamma från smuggling från utlandet. Substansen är narkotikaklassad och ingår i förteckningen N I i 1961 års allmänna narkotikakonvention, samt i förteckning II i Sverige. (sv) Оксиморфо́н или 14-гидроксидигидроморфинон (продается под торговыми марками Numorphan и Opana) — мощный полусинтетический опиоидный анальгетик. Препарат предназначен для уменьшения сильной боли. Облегчение боли после инъекции начинается примерно через 5–10 минут, после перорального приема препарат начинает действовать примерно через 30 минут (и длится около 3–4 часов). Период полувыведения оксиморфона намного быстрее при внутривенном введении, и поэтому препарат чаще всего используется перорально. Как и оксикодон, который метаболизируется в оксиморфон, оксиморфон имеет высокий потенциал злоупотребления. (ru) La Oximorfona, que se vende bajo las marcas Numorphan entre otras, es un potente analgésico opioide semisintético. El alivio del dolor después de la inyección comienza después de aproximadamente 5 a 10 minutos y 15 a 30 minutos después de la administración rectal, y dura aproximadamente de 3 a 4 horas para las tabletas de liberación inmediata y 12 horas para las tabletas de liberación prolongada. (es) Oxymorphone (sold under the brand names Numorphan and Opana among others) is a highly potent opioid analgesic indicated for treatment of severe pain. Pain relief after injection begins after about 5–10 minutes, after oral administration it begins after about 30 minutes, and lasts about 3–4 hours for immediate-release tablets and 12 hours for extended-release tablets. The elimination half-life of oxymorphone is much faster intravenously, and as such, the drug is most commonly used orally. Like oxycodone, which metabolizes to oxymorphone, oxymorphone has a high potential to be abused. (en) L’oxymorphone (Opana, Numorphan, Numorphone) ou 14-Hydroxydihydromorphinone est un puissant analgésique opioïde semi-synthétique d’abord développé en Allemagne vers 1914, brevetée aux États-Unis par la compagnie pharmaceutique Endo Pharmaceuticals en 1955 et introduite sur le marché américain en janvier 1959 et par la suite dans de nombreux autres pays à travers le monde. Dans certains pays, l’oxymorphone est distribué sous le nom de Numorphan et Numorphan Oral. Il diffère de la morphine au niveau des effets secondaires car il semble produire moins de sédation, de démangeaisons et d’autres effets du à une libération excessive d’histamine, comme tous les opiacés. Selon le patient, il peut créer plus ou moins de nausée et vomissement que la morphine. (fr) |
| rdfs:label | أوكسي مورفون (ar) Oxymorphon (de) Oximorfona (es) Oxymorphone (fr) Ossimorfone (it) Oxymorphone (en) Oksymorfon (pl) Оксиморфон (ru) Oximorfon (sv) |
| rdfs:seeAlso | dbr:Oxycodone |
| owl:differentFrom | dbr:Oxymorphazone |
| owl:sameAs | freebase:Oxymorphone http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01192 yago-res:Oxymorphone wikidata:Oxymorphone dbpedia-ar:Oxymorphone http://azb.dbpedia.org/resource/اوکسیمورفون dbpedia-cy:Oxymorphone dbpedia-de:Oxymorphone dbpedia-es:Oxymorphone dbpedia-fi:Oxymorphone dbpedia-fr:Oxymorphone dbpedia-hr:Oxymorphone dbpedia-it:Oxymorphone dbpedia-pl:Oxymorphone dbpedia-ro:Oxymorphone dbpedia-ru:Oxymorphone dbpedia-sh:Oxymorphone dbpedia-sr:Oxymorphone dbpedia-sv:Oxymorphone dbpedia-th:Oxymorphone dbpedia-tr:Oxymorphone https://global.dbpedia.org/id/3v5ej |
| prov:wasDerivedFrom | wikipedia-en:Oxymorphone?oldid=1115787483&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/Oxymorphone2DCSD.svg wiki-commons:Special:FilePath/Oxymorphone3DanJ.gif |
| foaf:isPrimaryTopicOf | wikipedia-en:Oxymorphone |
| is dbo:wikiPageRedirects of | dbr:OPANA_ER dbr:Numorphan dbr:Opana_ER dbr:Opana_IR dbr:14-Hydroxydihydromorphinone dbr:Oxymorphine dbr:Oxymorphone_Hydrochloride dbr:Oxymorphone_hydrochloride |
| is dbo:wikiPageWikiLink of | dbr:Ampoule dbr:Psychoactive_drug dbr:Scott_Gottlieb dbr:List_of_compounds_with_carbon_number_17 dbr:List_of_drugs_banned_by_the_World_Anti-Doping_Agency dbr:List_of_films_released_posthumously dbr:Regulation_of_therapeutic_goods dbr:Hydrocodone dbr:Hydromorphone dbr:List_of_deaths_from_drug_overdose_and_intoxication dbr:List_of_opioids dbr:Pentamorphone dbr:Decree-Law_15/93 dbr:Intractable_pain dbr:List_of_hazing_deaths_in_the_United_States dbr:Noroxymorphone dbr:OPANA_ER dbr:Numorphan dbr:14-Methoxydihydromorphinone dbr:Controlled_Substances_Act dbr:MedPage_Today dbr:Opana dbr:Opiate dbr:Opana_ER dbr:Chris_Leben dbr:Chyna dbr:Codeine dbr:Equianalgesic dbr:George_Hickenlooper dbr:Morphinan dbr:Morphine dbr:Nalbuphine dbr:Nalmexone dbr:Naloxone dbr:Naltrexone dbr:Controlled_Drugs_and_Substances_Act dbr:The_Rev dbr:Thebacon dbr:Thebaine dbr:Total_synthesis_of_morphine_and_related_alkaloids dbr:Opium_Law dbr:1914 dbr:1914_in_science dbr:Anderson_Silva dbr:Lil_Peep dbr:Single_Convention_on_Narcotic_Drugs dbr:Austin,_Indiana dbr:Celebrity_Rehab_with_Dr._Drew dbr:Thrombotic_thrombocytopenic_purpura dbr:Drug_policy_of_India dbr:Drug_test dbr:Drugs_controlled_by_the_German_Betäubungsmittelgesetz dbr:Drugs_controlled_by_the_UK_Misuse_of_Drugs_Act dbr:3,14-Diacetyloxymorphone dbr:3-Acetyloxymorphone dbr:3_Doors_Down dbr:7-Spiroindanyloxymorphone dbr:Acetylpropionylmorphine dbr:Analgesic dbr:Anesthetic dbr:Oxycodone dbr:Oxycodone/aspirin dbr:Oxymorphazone dbr:Oxymorphol dbr:Oxymorphone-3-methoxynaltrexonazine dbr:Pain_ladder dbr:List_of_German_inventions_and_discoveries dbr:List_of_MeSH_codes_(D03) dbr:List_of_Schedule_II_drugs_(US) dbr:Prescription_drug dbr:Prohibition_of_drugs dbr:HIV/AIDS_in_the_United_States dbr:Harrow_(TV_series) dbr:Heroin dbr:James_Irvin_(fighter) dbr:Teva_Pharmaceuticals dbr:ATC_code_N02 dbr:Chloroxymorphamine dbr:Justin_Levens dbr:Karo_Parisyan dbr:Laudanum dbr:Misuse_of_Drugs_Act_1977 dbr:Diacetyldihydromorphine dbr:Dong_Hyun_Kim dbr:C17H19NO4 dbr:Methadone dbr:Omeprazole dbr:Opioid dbr:Opioid_epidemic_in_the_United_States dbr:Sedative dbr:Semorphone dbr:Pain_management dbr:List_of_veterinary_drugs dbr:Poppy_straw dbr:UFC_Fight_Night:_Silva_vs._Irvin dbr:Papaver_bracteatum dbr:List_of_drugs:_Ox–Oz dbr:Opana_IR dbr:14-Hydroxydihydromorphinone dbr:Oxymorphine dbr:Oxymorphone_Hydrochloride dbr:Oxymorphone_hydrochloride |
| is gold:hypernym of | dbr:Oxymorphol |
| is owl:differentFrom of | dbr:Oxymorphazone |
| is foaf:primaryTopic of | wikipedia-en:Oxymorphone |
